# BioFluidica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biofluidica

- Industry: Biotechnology
- Headquarters: Lawrence, US
- Website: www.biofluidica.com
- Total disclosed funding: $3.5M
- Latest round: Series B (Nov 19, 2021)
- Investors on record: 1

## About

Based in California, US, and founded in 2006, BioFluidica, Inc. is a biotechnology company developing a diagnostic platform allowing for disease management and diagnosis. Steven A. Soper is the co-founder of the company, and Rolf Muller serves as its CEO. In February 2022, BioFluidica, Inc. raised USD 6 million in series B, led by returning investor Base, with participation from other unspecified investors.

The company develops a liquid biopsy platform that allows for the separation and analysis of all liquid biopsy biomarkers on a single completely automated platform, including cells, exosomes, and cfDNA. The Biofluidica platform has been clinically verified on 9 distinct cancer and pregnant patient samples, and it is being used for a wide range of research applications in the field of liquid biopsy.

The company plans to use the series B funding received in February 2022 to support the commercialization of its LiquidScan and the development of its advanced handheld Covid-19 detection device for at-home testing.

## Funding rounds

- Series B, Nov 19, 2021, $3.5M — BASE

## Investors

- BASE (https://capitalatlas.ai/funds/base) — Series B